Platelet-activating factor (PAF) has been implicated in the pathogenesis of gastrointestinal diseases such as necrotizing enterocolitis, Crohn's disease, and ulcerative colitis. However, neither the physiologic role of PAF in the intestine, nor the mechanisms by which PAF participates in the pathogenesis of disease are well understood. The aim of the present study was to determine the direct effect of PAF on intestinal epithelial cell ion transport, and to delineate the mechanisms of regulation. Ion transport was evaluated by measuring short circuit current (I sc ) in HT29-CL19A cell monolayers using Ussing chambers. PAF receptor polarity was assessed using domain-selective biotinylation followed by immunoprecipitation and streptavidin blotting of intact epithelial monolayers. PAF (1-200 M) stimulated I sc that followed the direction of a Cl Ϫ gradient and was specifically inhibited by the Cl Ϫ channel blockers glybenclamide, 2,2' iminodibenzoic acid and 4,4' diisothiocyanostilbene-2, 2' disulfonic acid, but was unaffected by the inhibition of prostaglandin synthesis with indomethacin. Stimulated I sc was only detected after apical addition of PAF, correlating with the results of biotinylation experiments indicating an exclusive apical polarity of the PAF receptor. PAF receptor antagonists CV6209 and octylonium bromide abolished PAF-stimulated I sc . Thus, mucosal acting PAF directly and specifically stimulates ion transport via activation of an apical Cl Ϫ channel in intestinal epithelial cell monolayers independent of prostaglandin biosynthesis. Abbreviations DIDS, 4,4' diisothiocyanostilbene-2, 2' disulfonic acid DPC, 2,2' iminodibenzoic acid IBD, inflammatory bowel disease I sc , short circuit current NEC, necrotizing enterocolitis PAF, platelet-activating factor PAF-AH, platelet-activating factor acetylhydrolase PAFR, platelet-activating factor receptor PBSCM, PBS supplemented with 1 mM CaCl 2 and 1 mM MgCl 2 pIGR, polymeric immunoglobulin receptor R te , transepithelial resistance PAF 1-O-alkyl-2-acetyl-sn glycero-3-phosphocholine is a phospholipid intra-and intercellular mediator implicated in the pathology of intestinal diseases such as NEC (1) and IBD (2) . It has been shown that PAF levels are elevated in infants with NEC (3). In rats, exogenous PAF given intravenously results in ischemic bowel necrosis (4) . Furthermore, studies using a rat model of NEC have shown that enteral administration of PAFR antagonists reduces the incidence of NEC (5, 6) . Recently, elevated PAF levels have been found in stool samples of patients with IBD (2) . Correlating with these findings, decreased levels of the PAF degrading enzyme, PAF-AH, have been observed in the distal ileum and serum samples of patients suffering from Crohn's disease (7) . In addition, lexipafant, a PAFR antagonist significantly reduced mucosal damage in an experimental model of colitis (8) .
Once activated, PAF initiates production of other inflammatory mediators such as tumor necrosis factor-␣, prostaglandins, thromboxane, and complement. It is unknown, however, whether the pathologic consequences of elevated PAF levels in the intestine are only the result of the initiation of an inflammatory cascade, or whether PAF itself may have a direct effect on intestinal epithelial cells. Other inflammatory mediators have been shown to alter critical hallmark functions of the intestinal epithelium, e.g. ion transport (9, 10) . Studies of PAF on tissue explants have also implied PAF induced ion transport. Notably, isolated rat jejunum (11) as well as human, rabbit, and rat colon have all demonstrated PAF-stimulated Cl Ϫ secretion (12-14).
However, despite extensive investigation of the effects of PAF on tissue and organ systems, specific effects at the intestinal epithelial cell level are poorly understood. It is difficult to extrapolate a direct PAF effect on epithelial cells from studies on tissue specimens because tissue samples incorporate multiple cell types with many interactions. PAF has been shown to stimulate Cl Ϫ secretion in human and rat colonic explants, but these effects were blocked by indomethacin and by a thromboxane A 2 synthase inhibitor, implying a significant role for intermediary mediators (12, 13) . Thus, it is unclear at present whether PAF-induced transepithelial Cl Ϫ transport in intact intestine represents a direct interaction of PAF with intestinal epithelial cells.
PAFR are abundantly expressed in the epithelial cells of the small intestine and colon, as well as in cultured epithelial cells lines (15) . To examine the effect of PAF on ion transport, specifically in intestinal epithelial cells, we mounted HT29-CL19A human colonic adenocarcinoma cell monolayers in Ussing chambers and measured PAF-induced transepithelial ion transport. Specifically, we determined that PAF directly stimulates transcellular active ion transport, documented PAFR expression and apical polarity in epithelial cell monolayers, and identified Cl Ϫ as the charge carrier for PAF-induced ion transport. Epithelial cell culture. HT29-CL19A cells originate from the subcloning of a human colonic adenocarcinoma cell line and display a highly differentiated phenotype, unlike the original HT29 cells (16) . Cells were cultured in Dulbecco's modified Eagle media with 10% fetal bovine serum, penicillin 50 U/mL, and streptomycin 50 g/mL. Cells were grown at 37°C in a 5% CO 2 atmosphere. Media was replaced every 48 h, and cells were passaged every 7 d. For Ussing chamber experiments, 200 L of cell suspension containing 5 ϫ 10 5 cells was plated on top of six-well Snapwell filters (12-mm diameter, 0.4-m pore size, Corning Life Sciences, Acton, MA, U.S.A.). Culturing HT29-CL19A cells for 8 -11 d resulted in the formation of a polarized epithelial monolayer with welldeveloped mucosal and serosal membranes. HT29-CL19A monolayers were studied when resistances were Ͼ250 ⍀/cm 2 .
MATERIALS AND METHODS

Materials. DIDS was obtained from
I sc and R te measurements. After 8 -11 d of incubation, current and resistance measurements were obtained using an Ussing chamber system equipped with digital data acquisition software that also allows software control of clamp electronics (Physiologic Instruments, San Diego, CA, U.S.A.). A blank filter was initially inserted to make adjustments for fluid resistance and voltage asymmetry, and then filters with cell monolayers were placed between chambers filled with 3 mL of buffer solution. The standard physiologic buffer used contained 116 mM NaCl, 5.4 mM KCl, 0.4 mM MgCl 2 , 1.8 mM CaCl 2 , 5.5 mM Glucose, 26 mM NaHCO 3 , and 0.9 mM NaH 2 PO 4 . I sc was recorded in voltage clamp mode. R te was evaluated using 10-mV pulses every 20 s. I sc recordings presented in the figures are representations of single readings and are the result of digital data acquisition of actual current before the voltage pulse; therefore, the current spikes elicited by the voltage pulses are not displayed. When transport was evaluated under asymmetric buffer ion conditions, compensation for bridges and fluid resistance was performed under identical asymmetric ion conditions. I sc and R te were recorded and analyzed using the Acquire and Analyze program, (Physiologic Instruments). A positive current was defined as the movement of negative ions from the serosal to the mucosal compartment or the flow of positive ions in the opposite direction.
Identification of PAFR mRNA using Reverse-Transcriptase PCR and restriction digestion mapping. Total RNA was extracted by RNA-extracting agent STAT-60 (Tel Test B, Friendswood, TX, U.S.A.), according to the manufacturer's instructions. RNA integrity was verified by electrophoresis in 1% agarose gel. For each sample, 3 g total RNA was reverse transcribed using Moloney-murine leukemia virus reverse transcriptase (Invitrogen, Carlsbad, CA, U.S.A.). cDNA was amplified by 35 cycles of PCR with AmpliTaq DNA polymerase using sense 5'-TATAACCGCTTCCAGGCAGT-3' and antisense 5'-GAAACAGTAGATAACAGGGTC-3' primers, respectively (17) . The size of the predicted PAFR PCR product is 549 bp. After PCR, the PAFR PCR products were digested with PuvII or AvaII restriction enzymes at 37°C for 60 min and were separated by electrophoresis on a 1.2% agarose gel containing 1:10,000 diluted SYBR Green I (QIAGEN, Valencia, CA, U.S.A.).
Cell-surface biotinylation, immunoprecipitation, and streptavidin blotting of PAFR. Cell-surface biotinylation was performed using cells grown on Snapwell membranes as described for Ussing chamber experiments. Cells were washed in ice-cold PBSCM. Sulfo-NHS-LC-biotin (1 mM) in PBSCM was then added to either the mucosal or serosal chamber. After incubation for 30 min on ice, cells were washed in ice-cold PBSCM, and blocked with 100 mM glycine in PBSCM for 30 min on ice. For immunoprecipitation, cells were lysed for 30 min at 4°C in buffer containing 20 mM HEPES, 150 mM NaCl, 1 mM EDTA, and 1% Nonidet P-40 (pH 7.4) supplemented with 10 g/mL aprotinin, 10 g/mL leupeptin, and 10 g/mL 4-(2-aminoethyl)-benzenesulfonyl fluoride. Lysates were then centrifuged at 16,000 ϫ g for 5 min, and supernatants were supplemented with 1/4 volume of 5ϫ RIPA buffer [250 mM Tris (pH 7.5), 120 mM sodium deoxycholate, 600 mM NaCl, 5% Triton X-100 (vol./vol.) and 0.5% SDS]. After adding 0.5 156 g anti-PAFR polyclonal antibody, 10 L of anti-pIGR containing ascites fluid (basolateral biotinylation positive control), or an equal concentration of rabbit/mouse nonimmune IgG (negative control), lysates were incubated at 4°C for 1 h on a rotating shaker, followed by the addition of 20 L protein G agarose (50% slurry) and incubation for an additional 1 h. Beads were collected with centrifugation at 1000 ϫ g for 2 min, and washed three times using 1ϫ RIPA. Pellets were resuspended in equal volumes of reducing SDS sample buffer [60 mM Tris (pH 6.8), 2% SDS, 5% ␤-mercapto-ethanol, 0.1% bromphenol blue, 50% glycerol], heated for 5 min to 95°C, resolved on reducing SDS-PAGE, then transferred to polyvinylidene fluoride membranes (Bio-Rad, Cambridge, MA, U.S.A.). Membranes were overlaid with streptavidin-horse radish peroxidase conjugates (100 ng/mL), incubated for 1 h, then washed three times with 0.5% Tween 20 in Tris-buffered saline. Blots were visualized using the ECL Plus chemiluminescence reagent ( 
RESULTS
Comparison of PAF-and cAMP-induced I sc . HT29-CL19A monolayers exhibited a 7.9 Ϯ 0.2 A/cm 2 baseline I sc . Monolayers were treated with PAF (10 M) in sequence with cpt-cAMP (300 M), a cell-permeable cAMP analogue. The concentration of cpt-cAMP was chosen based on previous dose response data (not shown) to determine whether PAF elicits additional current after maximum activation by cAMP, the best-characterized regulator of ion transport in this cell line (18, 19) . The order was varied to see whether there was any cumulative effect (Fig. 1a) . PAF (10 M) alone stimulated a ⌬I sc to a maximum of 22.0 Ϯ 2.8 A/cm 2 , followed by decay to a stable 4.5 Ϯ 0.7 A/cm 2 ⌬I sc , which persisted for Ͼ30 min. PAF added after maximally activated cAMP-induced current resulted in an additional 17.7 Ϯ 3.3 A/cm 2 current. A chloride channel blocker, glybenclamide (500 M), added to the mucosal side returned I sc to the baseline level, suggesting that Cl Ϫ is the principal charge carrier in these effects (n ϭ 6 -10).
The dose dependence of PAF-stimulated I sc . Previously published reports on PAF-mediated changes in various cell types demonstrate two very distinct ranges of dose responses. Effective doses in the 1-100 M range have been observed primarily in epithelial tissues (20 -23) , whereas other cell lines exhibit several orders of magnitude higher sensitivity to PAF, in the 10 -500 nM range (24 -26) . To correlate our observations with these earlier studies, we evaluated the dose response relationship of PAF-elicited I sc in HT29-CL19A cells. PAF regulated ion transport at doses ranging from 0.1 to 200 M in this cell line (Fig. 1b) . Vehicle alone (ethanol) had no effect on I sc (not shown). Curve fitting to the results of dose response observations using the Michaelis-Menten equation revealed a K s for PAF-induced I sc of 46 M (R 2 ϭ 0.91). Identification of the charge carrier responsible for PAF currents. To investigate more thoroughly the charge carrier associated with PAF-induced currents, we influenced the driving forces for chloride in our system, and evaluated the effects of chloride channel inhibitors on the current. Low-chloride (7.6 mM) buffer was prepared by substituting sodium gluconate for NaCl in the standard physiologic buffer. The effect of PAF on I sc was measured with or without permeabilization of the basolateral membrane with 100 M amphotericin B for 30 min before the addition of other agents, and in the presence of a chloride gradient across the monolayer. The chloride gradient was created by placing low Cl Ϫ buffer in either the serosal or the mucosal chamber, while maintaining physiologic Cl Ϫ concentration in the opposing chamber. PAF added in the presence of serosal amphotericin and a serosal to mucosal Cl Ϫ gradient resulted in a 30.5 Ϯ 2.4 A/cm 2 ⌬I sc , whereas reversal of the gradient in the presence of serosal amphotericin resulted in a reversed current Ϫ13.5 Ϯ 1.7 A/cm 2 ( Fig. 2a) . To ensure that the PAF-induced current was not due to changes in paracellular conductance, the effect of PAF on I sc was also evaluated without permeabilization of the basolateral membrane. As depicted by the dashed line in Figure 2a , PAF did not elicit any detectable change in I sc (Ϫ0.47 Ϯ 0.05 A/cm 2 , n ϭ 6) when low Cl Ϫ buffer was placed in the serosal chamber without permeabilization of the basolateral membrane, indicating that PAF-induced current is due to transcellular, and not paracellular ion transport. The Cl Ϫ channel blockers glybenclamide (500 M), DPC (500 M), and DIDS (600 M) blocked PAF-induced stable ⌬I sc by 81 Ϯ 8%, 80 Ϯ 9%, and 80.6 Ϯ 9.2%, respectively (Fig. 2b, all significant at p Ͻ 0.05, n ϭ 4) . All three inhibitors were added only in the mucosal chamber, with simultaneous addition of solvent to the opposing chamber to avoid an effect on basolateral transporters. Solvents added to both sides had no significant effect, and none of the channel blockers affected baseline currents (data not shown).
PAF stimulates I sc directly and specifically in HT29-CL19A cells. PAF can be metabolized in various ways, and its by-products may affect ion transport. HT29-CL19A monolayers were treated with the PAF analogue carbamyl PAF (27) or with PAF in the presence of the degrading enzyme PAF-AH (28) to confirm a direct and specific effect of PAF on I sc . Carbamyl PAF at 10 M elicited 27.6 Ϯ 2.6 A/cm 2 ⌬I sc , whereas including PAF-AH in the chamber before adding PAF blocked PAF-induced ⌬I sc to 2.6 Ϯ 1.1 A/cm 2 (p Ͻ 0.05, n ϭ 4).
The stimulation of Cl ؊ transport by PAF is not mediated by prostaglandin synthesis. Earlier studies indicating that PAF applied to the serosal side of intestinal explants stimulates Cl Ϫ transport found that this stimulatory effect required prostaglandin synthesis, and, therefore, was blocked by indomethacin. Although the stimulation of transepithelial Cl Ϫ transport by PAF exhibited very different characteristics, to further differentiate the direct mucosal activation of I sc by PAF from the previously described serosal indirect effect, we evaluated the potential role of prostaglandin synthesis. After pretreatment and the subsequent continuous presence of 10 M indomethacin, both the time course and magnitude of PAF-stimulated I sc was indistinguishable from I sc in the absence of indomethacin (Fig. 3, a and b) . Interestingly, indomethacin caused a small but significant increase in the cAMP-stimulated I sc .
The effect of PAFR antagonists on PAF-induced I sc . Given that the sensitivity of PAF-dependent activation of ion transport in epithelial cells is strikingly different from the activation of PAFR in endometrial cells, T and B lymphocytes, and macrophages, we evaluated the effect of PAFR antagonists to confirm a specific PAFR-mediated effect. CV6209 (20 M) and octylonium bromide (40 M) almost completely abolished the stimulation of I sc by 20M PAF (Fig. 4a) . PAF alone induced 26.4 Ϯ 3.0 A/cm 2 ⌬I sc (n ϭ 10), whereas pretreatment with CV6209 or octylonium bromide reduced PAFinduced ⌬I sc to 4.0 Ϯ 1.3 A/cm 2 and 4.7 Ϯ 2.6 A/cm 2 , respectively (p Ͻ 0.01). Neither receptor antagonist had a significant effect on cAMP-induced ion transport in HT29-CL19A cells, indicating a specific inhibitory effect on PAFinduced ion transport.
PAF stimulates I sc only when added to the mucosal surface of HT29-CL19A monolayers. To determine the polarity of PAF-induced I sc , PAF was added to either the mucosal or serosal chamber and resulting I sc changes were recorded and quantified. When PAF (10 M) was only added to the mucosal side of the monolayer, mean ⌬I sc was 35.0 Ϯ 5.2 A/cm 2 , whereas PAF (10 M) added only to the serosal chamber resulted in no current (⌬I sc ϭ 0.2 Ϯ 0.1 A/cm 2 , Fig. 4b ). Analysis of PAFR expression and polarity. We next tested whether HT29-CL19A cells express the same PAFR identified in other cell types. Total RNA was isolated from cultured cells and analyzed by reverse-transcriptase (RT)-PCR using primers 158 designed to hybridize with the known human PAFR. The authenticity of PCR products was verified using restriction digest mapping. Figure 5a illustrates that HT29-CL19A cells constitutively express PAFR transcripts as shown by amplification of the predicted 549 bp fragment by RT-PCR. The fragment was cut by PvuII (417 bp and 132 bp), and AvaII (427 bp and 122 bp), as predicted based on the published sequence (29) .
We then used domain-selective biotinylation to detect PAFR present on either the apical or basolateral plasma membrane. On streptavidin blots, the characteristic PAFR 68-kD band (15, 30) was detected from lysates of cells that were exposed to the biotinylating agent on their apical surface (Fig. 5b) . The correct-size protein band was not detected from cell lysates that were not exposed to the biotinylating reagent, or when nonimmune IgG was used instead of the anti-PAFR antibody. In addition, this band was not detected from cells biotinylated from the basolateral side; only a faint lower molecular weight band was detected that was also present in the nonimmune control. Polymeric IGR was used as a positive control to confirm biotinylation of basolateral proteins across the supporting membrane (Fig. 5c) .
DISCUSSION
Vectorial ion transport is one of the hallmark functions of intestinal epithelium. Na ϩ and Cl Ϫ are the two solutes transported in the largest quantities, and disordered Cl Ϫ secretion is the basis for several diseases. Exaggerated Cl Ϫ secretion causes the severe secretory diarrhea associated with Vibrio cholerae and Escherichia coli toxins. Conversely, when Cl Ϫ secretion is impaired, as in cystic fibrosis, an intestinal obstruction such as meconium ileus can result (31) . In addition, Cl Ϫ secretion has been thought to be a participant in innate mucosal defense mechanisms against bacteria (32) .
A number of inflammatory mediators have been shown to regulate Cl Ϫ transport either by regulating the activity of ion channels, or by regulating their gene expression. PAF, a phospholipid mediator that has been implicated in the pathology of NEC, IBD, and asthma (2, 3, 33) , has been shown to activate Cl Ϫ transport in both intestinal explants and airway epithelial cells. To date, direct effects of PAF on ion transport of epithelial monolayers have been demonstrated only in airway epithelial cells (20) . The direct effect by PAF on airway epithelial cells has been demonstrated at micromolar concentrations and elicited from the mucosal side of the monolayers. The effect on intestinal transport has been thought to be mediated only indirectly via the stimulated production of mediators such as prostaglandins (12, 21) and thromboxanes (13) . The indirect effect of PAF on intestinal explants has only been observed from the serosal side at nanomolar concentrations. Merendino et al. (15) have previously demonstrated PAFR expression in the intestinal epithelium, and several studies have documented increased stool PAF content in patients with IBD compared with disease-free controls. Given the high-level expression of PAFR in the intestinal epithelium, we hypothesized that, in addition to previously documented indirect effects, PAF would have a direct effect on intestinal epithelial cells.
The purpose of our study was to characterize the role of PAF in the direct regulation of intestinal epithelial cell ion transport. We performed our experiments in the HT29-CL19A cell line; a well-described transformed human colonic crypt cell model (16, 34) . Our results demonstrate that PAF stimulates Cl Ϫ transport across monolayers of HT29-CL19A cells. PAF-induced I sc followed the direction of a Cl Ϫ gradient when basolateral plasma membranes were permeabilized, and was inhibited by the Cl Ϫ channel blockers glybenclamide, DPC, and DIDS. On the other hand, without the permeabilization of the basolateral plasma membrane and in the presence of a mucosal to serosal Cl Ϫ gradient, PAF did not elicit any current, excluding the possibility that increased paracellular permeability is responsible for the observed current. All three Cl Ϫ channel blockers inhibited PAF-induced I sc , even when only added to the mucosal compartment and in cells with permeabilized basolateral membranes, indicating that this inhibition was not a result of interference with basolateral loading mechanisms. The elicited PAF I sc was not affected by indomethacin, confirming a direct effect not requiring prostaglandin synthesis. Thus, our results indicate that PAF-induced I sc results from the opening of a chloride channel in the apical cell membrane, and represents vectorial Cl Ϫ transport in a serosal to mucosal direction. Several Cl Ϫ channels have been identified in intestinal cells and the precise identification of the ion channel opened after activation by PAF was beyond the scope of this study. Further studies using techniques such as patch clamping and single-channel analysis may be helpful in identifying the specific Cl Ϫ channel opened by PAF.
All of our observations suggest that in HT29-CL19A cells, PAF activates Cl Ϫ transport via a specific receptor-mediated effect. We confirmed the presence of PAFR mRNA in HT29-CL19A cells by RT-PCR and the PAFR protein by immunoprecipitation and streptavidin blotting of the biotinylated receptor. The effect of PAF on I sc was mimicked by carbamyl-PAF, a nonmetabolizable analogue of PAF, was abolished by PAF-AH, a PAF degrading enzyme, and was inhibited by the PAFR antagonists CV6209 and octylonium bromide. The PAFR antagonists did not have an effect on cAMP-induced I sc , verifying the specificity of their effect. Furthermore, the observed apical polarity of the PAFR protein was consistent with the functional effect, i.e. PAF activated I sc only from the mucosal chamber.
Yet, as previously mentioned, significant differences exist between PAF-induced effects in epithelial cells compared with PAFR activation in other cell types. We observed stimulation of ion transport by PAF at micromolar concentrations in cultured intestinal epithelial cells similar to that seen in cultured bronchial epithelial cells (20) , but different from the high-affinity activation identified in Chinese hamster ovary cells transfected with PAFR, endometrial cells, T and B lymphocytes, primary hippocampal neurons, macrophages (24 -26, 35) , and the indirect serosal effects observed in rat and human tissue explants (12, 13) . The mechanism reducing the affinity of PAFR to its ligand in the apical plasma membranes of intestinal and airway epithelial cells 160 compared with other nonepithelial cells is unknown. Experimental evidence suggests that G proteins or membrane lipids can modify the affinity of PAF to PAFR. When the receptor is bound to heterotrimeric G proteins, it exhibits high PAF affinity, but this affinity is reduced when the G proteins dissociate (36) . Also, treatment of PAFRexpressing cells with polyunsaturated fatty acids that alter the lipid composition of extracted membranes changes the binding affinity of PAF to PAFR (37) . Therefore, either the profile of associated heterotrimeric G proteins or the surrounding lipids could influence the affinity of PAFR to PAF in different cell types. Alternatively, a second, low-affinity binding site might exist on the PAFR that could explain the effects observed exclusively in cultured epithelial cells.
The in vivo relevance of low-affinity PAFR on the intestinal mucosal surface may be controversial. Although there is no information available regarding the exact concentrations of PAF at the mucosal surfaces of intestinal epithelial cells, it is likely that relatively high concentrations might exist, especially under pathologic conditions. The two key enzymes involved in the biosynthesis of PAF, the secretory form of type II phospholipase A 2 and PAF acetyltransferase, have both been shown to be expressed by intestinal epithelial cells (38, 39) . Type II phospholipase A 2 is expressed in Paneth cells, and its expression is increased in ulcerative colitis (38) . Indeed, cultured colonic biopsies from ulcerative colitis patients have been shown to produce PAF (40) at 0.8 nmol/g (tissue) /h rates. In another study, tissue concentrations of PAF in micromolar concentrations were found in mucosal scrapings of biopsy specimens from patients with ulcerative colitis (41) . Escherichia coli and other bacteria that are commonly found in the gastrointestinal tract are also extremely capable of producing PAF (42, 43) . PAF can be readily detected in stool from patients with ulcerative colitis and Crohn's disease (2) . Considering that the PAFdegrading enzyme PAF acetylhydrolase is present in the intestinal lumen, any detectable PAF in the stool suggests potentially much higher concentrations upstream in the intestinal tract. Therefore, a low-affinity PAFR in the luminal plasma membrane of epithelial cells might indicate an adaptation specifically designed to be activated only under potentially high levels of PAF that might exist under pathologic conditions in the intestinal lumen.
In conclusion, PAF directly and specifically stimulates Cl Ϫ transport in intestinal epithelial cells through the opening of an apical chloride channel. This direct stimulation of Cl Ϫ transport can be elicited only by mucosal application of PAF, and the polarity of the functional effect correlates with our observation that PAFR is expressed in the apical domain of polarized HT29-CL19A cells. PAF-induced Cl Ϫ transport may represent a physiologic function, or may be related to PAFinduced mucosal injury. Further studies of the direct interactions of epithelial cells with PAF leading to a better understanding of the physiologic and pathologic roles of PAF in mucosal homeostasis may elucidate mechanisms of intestinal injury resulting from altered PAF metabolism.
